| Literature DB >> 22638994 |
Jong-Yeon Kim1, Bokyoung Kim, Ki-Soo Park, Ji-Young Choi, Jung-Ju Seo, Sun-Hee Park, Chan-Duck Kim, Yong-Lim Kim.
Abstract
BACKGROUND AND OBJECTIVES: This study was conducted to measure the level of health-related quality of life (HRQOL) and to reveal the association of self-efficacy and treatment satisfaction with it in Korean dialysis patients. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: The study subjects were 237 patients receiving either hemodialysis (HD) or peritoneal dialysis (PD) from two university hospitals, from February to June in 2010. We investigated HRQOL using the Korean version of Kidney Disease Quality of Life Short Form 36 (KDQOL-36), and self-efficacy and treatment satisfaction by self-administrative questionnaire and their dialysis-related variables by reviewing clinical records. The associations of self-efficacy and treatment satisfaction with HRQOL were assessed using multiple linear regression analysis.Entities:
Mesh:
Year: 2012 PMID: 22638994 PMCID: PMC3636437 DOI: 10.1007/s11136-012-0203-x
Source DB: PubMed Journal: Qual Life Res ISSN: 0962-9343 Impact factor: 4.147
Health-related quality of life (HRQOL) scores by general characteristics (unit: mean ± SD)
|
| Physical component summary | Mental component summary | Symptom/problem list | Effect of disease | Burden of disease | |
|---|---|---|---|---|---|---|
|
| ||||||
| Male | 128 (54.0) | 40.3 ± 9.4* | 45.3 ± 6.2 | 68.8 ± 17.2 | 58.7 ± 19.6 | 40.3 ± 28.0 |
| Female | 109 (46.0) | 37.8 ± 9.6 | 43.9 ± 7.4 | 66.1 ± 17.0 | 58.3 ± 19.6 | 42.1 ± 29.0 |
|
| ||||||
| <49 years | 66 (27.8) | 42.3 ± 8.9** | 44.1 ± 6.6 | 67.4 ± 19.5 | 58.3 ± 19.1 | 40.7 ± 19.1 |
| 50–59 years | 59 (24.9) | 40.1 ± 10.1 | 43.9 ± 7.7 | 69.4 ± 16.3 | 59.9 ± 20.8 | 43.6 ± 29.7 |
| 60–69 years | 62 (26.2) | 38.8 ± 9.1 | 45.4 ± 6.4 | 68.0 ± 15.2 | 57.6 ± 20.5 | 43.3 ± 28.8 |
| +70 years | 50 (21.1) | 34.1 ± 9.5 | 45.2 ± 6.6 | 64.9 ± 17.2 | 58.2 ± 18.0 | 36.5 ± 28.4 |
|
| ||||||
| Elementary or under | 52 (21.9) | 36.6 ± 9.7** | 43.6 ± 7.4 | 66.0 ± 14.7 | 60.0 ± 19.3 | 45.9 ± 31.3 |
| Middle school | 50 (21.1) | 37.0 ± 10.4 | 45.7 ± 6.1 | 63.8 ± 18.2 | 56.1 ± 22.8 | 45.0 ± 30.8 |
| High school | 80 (33.8) | 40.5 ± 8.9 | 43.9 ± 7.3 | 68.2 ± 17.8 | 57.8 ± 18.5 | 42.0 ± 28.0 |
| College or over | 55 (23.2) | 41.5 ± 9.5 | 45.7 ± 6.0 | 71.6 ± 16.9 | 60.2 ± 18.5 | 31.8 ± 21.7 |
|
| ||||||
| Yes | 68 (28.7) | 41.9 ± 8.7** | 44.3 ± 6.5 | 70.4 ± 17.6 | 60.6 ± 18.7 | 37.6 ± 24.9 |
| No | 169 (71.3) | 38.0 ± 9.6 | 44.7 ± 7.0 | 66.4 ± 16.9 | 57.6 ± 19.9 | 42.5 ± 29.7 |
| Total | 237 (100.0) | 39.1 ± 9.5 | 44.6 ± 6.8 | 67.6 ± 17.1 | 58.5 ± 19.6 | 41.1 ± 28.4 |
* p < 0.05, ** p < 0.01
HRQOL scores by disease-specific characteristics (unit: mean ± SD or Pearson’s correlation coefficient)
|
| Physical component summary | Mental component summary | Symptom/problem list | Effect of disease | Burden of disease | |
|---|---|---|---|---|---|---|
|
| ||||||
| HD | 172 (72.6) | 39.3 ± 9.7 | 44.6 ± 7.0 | 69.6 ± 16.6** | 59.5 ± 19.4 | 39.9 ± 27.7 |
| PD | 65 (27.4) | 38.7 ± 9.0 | 44.8 ± 6.4 | 62.1 ± 17.5 | 55.9 ± 20.0 | 44.3 ± 30.1 |
|
| ||||||
| <2 years | 93 (39.4) | 40.0 ± 9.7 | 44.0 ± 6.7 | 69.5 ± 16.7 | 58.6 ± 19.6 | 40.9 ± 28.3 |
| 2–5 years | 82 (34.7) | 39.0 ± 9.6 | 45.0 ± 7.1 | 68.0 ± 17.5 | 59.3 ± 19.9 | 43.0 ± 29.6 |
| >5 years | 62 (26.3) | 38.0 ± 9.1 | 45.1 ± 6.7 | 64.0 ± 16.6 | 57.3 ± 19.5 | 39.1 ± 27.3 |
|
| ||||||
| Hypertension | 69 (29.1) | 38.2 ± 9.8 | 45.4 ± 6.0 | 70.6 ± 14.9 | 61.5 ± 18.9 | 52.5 ± 32.9** |
| Diabetes | 94 (39.7) | 39.0 ± 9.1 | 45.5 ± 7.5 | 65.2 ± 17.7 | 57.7 ± 20.3 | 34.7 ± 24.1 |
| Glomerulonephritis | 25 (10.5) | 42.6 ± 11.3 | 42.4 ± 7.7 | 73.2 ± 18.1 | 59.5 ± 18.8 | 48.2 ± 29.9 |
| Others | 49 (20.7) | 38.9 ± 8.8 | 43.0 ± 5.6 | 65.1 ± 17.6 | 55.2 ± 19.6 | 43.7 ± 22.7 |
|
| ||||||
| Adequate | 171 (72.2) | 38.6 ± 9.6 | 44.4 ± 7.0 | 68.0 ± 17.4 | 57.4 ± 20.0 | 41.1 ± 29.5 |
| Inadequate | 39 (27.8) | 40.4 ± 9.3 | 45.3 ± 6.5 | 66.4 ± 16.5 | 61.4 ± 18.4 | 41.1 ± 25.5 |
|
| ||||||
| Yes | 5 (2.1) | 37.6 ± 5.4 | 50.0 ± 3.4 | 63.3 ± 18.2 | 45.6 ± 18.0 | 41.2 ± 29.2 |
| No | 232 (97.9) | 39.2 ± 9.6 | 44.5 ± 6.8 | 67.3 ± 17.1 | 58.8 ± 19.6 | 41.1 ± 28.5 |
|
| ||||||
| Yes | 22 (9.3) | 33.1 ± 9.5** | 46.7 ± 5.8 | 62.9 ± 16.2 | 57.2 ± 18.5 | 52.6 ± 32.4 |
| No | 215 (90.7) | 39.7 ± 9.4 | 44.4 ± 6.9 | 68.0 ± 17.2 | 58.6 ± 19.7 | 39.9 ± 27.8 |
|
| ||||||
| Yes | 199 (84.0) | 38.8 ± 9.3 | 44.6 ± 6.8 | 67.4 ± 16.6 | 57.1 ± 18.7 | 42.2 ± 28.3 |
| No | 38 (16.0) | 40.7 ± 10.7 | 44.5 ± 6.6 | 68.4 ± 19.8 | 65.9 ± 22.7 | 35.2 ± 28.5 |
|
| ||||||
| Yes | 16 (6.8) | 37.2 ± 9.4 | 47.7 ± 5.7 | 71.5 ± 10.8 | 65.4 ± 17.9 | 57.4 ± 28.3 |
| No | 221 (93.2) | 39.3 ± 9.4 | 44.4 ± 6.9 | 67.3 ± 17.5 | 58.0 ± 19.6 | 39.9 ± 28.1 |
|
| ||||||
| Yes | 119 (50.2) | 36.8 ± 8.8** | 45.3 ± 6.1 | 67.1 ± 15.6 | 56.9 ± 19.4 | 43.6 ± 30.7 |
| No | 118 (49.8) | 41.5 ± 9.7 | 44.0 ± 7.4 | 68.0 ± 18.7 | 60.1 ± 19.7 | 38.6 ± 25.8 |
|
| ||||||
| None | 25 (10.5) | 41.9 ± 10.9** | 45.5 ± 6.7 | 70.8 ± 18.9 | 61.1 ± 22.0 | 37.7 ± 26.2** |
| 1 Disease | 92 (38.8) | 41.7 ± 9.3 | 43.0 ± 7.6 | 68.1 ± 18.9 | 60.1 ± 20.0 | 39.1 ± 27.3 |
| 2 Diseases | 96 (40.5) | 37.2 ± 8.5 | 45.3 ± 6.1 | 66.0 ± 15.9 | 55.1 ± 18.4 | 38.0 ± 27.9 |
| +3 Diseases | 24 (10.1) | 34.0 ± 9.3 | 47.4 ± 5.6 | 68.2 ± 12.4 | 59.0 ± 18.6 | 64.6 ± 27.9 |
| Serum albumin levela | 3.76 ± 0.46a | 0.221** | -0.097 | 0.220** | 0.052 | -0.123 |
| Total | 237 (100.0) | 39.1 ± 9.5 | 44.6 ± 6.8 | 67.6 ± 17.1 | 58.5 ± 19.6 | 41.1 ± 28.4 |
* p < 0.05, ** p < 0.01
aSerum albumin level was expressed as “mean ± SD” and its association with HRQOL was analyzed by Pearson’s correlation coefficient
Correlation between self-efficacy, treatment satisfaction, and HRQOL (unit: Pearson’s correlation coefficient)
| Mean ± SD | Health-related quality of life | |||||
|---|---|---|---|---|---|---|
| Physical component summary | Mental component summary | Symptom/problem list | Effect of disease | Burden of disease | ||
| Treatment goal self-efficacy (range: 1–5) | 3.1 ± 0.6 | 0.19** | 0.16** | 0.23** | 0.19** | 0.16* |
| Treatment management self-efficacy(range: 1–5) | 3.2 ± 0.6 | 0.12 | 0.22** | 0.21** | 0.20** | 0.12 |
| Treatment satisfaction (range: 0–60) | 32.7 ± 11.4 | 0.27** | 0.18** | 0.12 | 0.28** | −0.13 |
* p < 0.05, ** p < 0.01
Association of self-efficacy, treatment satisfaction, and HRQOL by multiple linear regression analysis
| Physical component summary | Mental component summary | Symptom/problem list | Effect of disease | Burden of disease | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| b | SE |
| b | SE |
| b | SE |
| b | SE |
| b | SE |
| |
| Treatment goal self-efficacya | 1.15 | 1.02 | 0.260 | 2.03 | 0.81 | 0.013 | 4.97 | 1.94 | 0.011 | 4.89 | 2.31 | 0.037 | 12.23 | 3.19 | <0.001 |
| Treatment management self-efficacya | 0.67 | 0.93 | 0.486 | 2.73 | 0.74 | <0.001 | 4.89 | 1.81 | 0.007 | 4.57 | 2.15 | 0.035 | 8.58 | 3.02 | 0.005 |
| Treatment satisfactiona | 0.14 | 0.05 | 0.005 | 0.10 | 0.04 | 0.023 | 0.18 | 0.10 | 0.076 | 0.50 | 0.11 | 0.001 | −0.22 | 0.17 | 0.185 |
aIndividually adjusted by sex, age, educational level, job, dialysis method, dialysis duration, cause of ESRD, dialysis adequacy, serum albumin level, existence of acute myocardial infarction, ischemic heart disease, stroke, hypertension, diabetes, and number of co-disease